HC Wainwright Reaffirms Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

HC Wainwright reaffirmed their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research note released on Friday morning,Benzinga reports. They currently have a $19.00 target price on the stock.

Other equities research analysts also recently issued research reports about the company. D. Boral Capital reissued a “buy” rating and set a $31.00 price target on shares of NRx Pharmaceuticals in a research report on Tuesday, January 28th. Ascendiant Capital Markets upped their target price on NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd.

NRx Pharmaceuticals Trading Up 13.5 %

NRx Pharmaceuticals stock opened at $2.35 on Friday. NRx Pharmaceuticals has a 12 month low of $1.10 and a 12 month high of $6.01. The stock’s 50 day moving average is $3.02 and its 200-day moving average is $2.02. The company has a market capitalization of $39.75 million, a price-to-earnings ratio of -1.10 and a beta of 1.22.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its earnings results on Friday, March 14th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.10). As a group, equities research analysts predict that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Insider Activity

In related news, Chairman Jonathan C. Javitt acquired 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The stock was acquired at an average cost of $1.17 per share, for a total transaction of $46,800.00. Following the completion of the acquisition, the chairman now directly owns 84,634 shares of the company’s stock, valued at approximately $99,021.78. This trade represents a 89.62 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 19.00% of the stock is owned by corporate insiders.

Institutional Trading of NRx Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Squarepoint Ops LLC acquired a new stake in NRx Pharmaceuticals in the fourth quarter valued at $56,000. Millennium Management LLC acquired a new stake in NRx Pharmaceuticals during the 4th quarter worth about $61,000. Anson Funds Management LP grew its holdings in NRx Pharmaceuticals by 30.3% during the 4th quarter. Anson Funds Management LP now owns 185,660 shares of the company’s stock worth $408,000 after acquiring an additional 43,135 shares during the period. AdvisorShares Investments LLC grew its holdings in NRx Pharmaceuticals by 138.5% during the 4th quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock worth $683,000 after acquiring an additional 180,229 shares during the period. Finally, Sassicaia Capital Advisers LLC acquired a new stake in NRx Pharmaceuticals during the 4th quarter worth about $33,000. 4.27% of the stock is currently owned by institutional investors and hedge funds.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.